Business Wire

Joint Tsinghua-Liverpool Research Team Discover New Charge Storage Mechanism

16.8.2021 12:00:00 EEST | Business Wire | Press release

Share

Due to their high energy density and low cost, metal-air batteries are one of the most promising power sources of the future. A joint Tsinghua-Liverpool research team has recently developed a new charge storage mechanism that allows rechargeability within calcium-air batteries - a major step forward in battery technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210816005031/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lu in Prof Hu’s lab where he set up experiments to cross compare results obtained at NTHU and at UoL.(Photo: National Tsing Hua University)

This discovery has been published in Chemical Science. The lead author of the paper, Yi-Ting Lu, is a joint doctoral student at Tsinghua and Liverpool, whose supervisors are Prof. Chi-Chang Hu (Department of Chemical Engineering, NTHU) and Prof. Laurence Hardwick (Department of Chemistry, UoL).

A major breakthrough related to Ca-air batteries

Prof. Hu said conventional lithium-ion batteries have a limited practical capacity. Thereby many researchers are working on developing alternative battery technologies. Their focus is on metal-air batteries based on zinc, lithium, sodium, potassium, calcium, magnesium, and aluminum. The advantage of the calcium-air battery is its high specific energy—five times that of traditional lithium-ion batteries. However, the feasibility of calcium-air batteries remains hampered by one major drawback—it cannot be recharged.

Lu explained that metal-air batteries are electrochemical cells usually using an active metal as the negative electrode, and a porous carbon material in contact with the air as the positive electrode. When the metal oxidized the oxygen at the positive electrode is reduced, generating electric current.

After completing his first year of doctoral studies at NTHU, Lu enrolled at the Stephenson Institute for Renewable Energy at UoL in September 2018. Under the supervision of Prof. Hardwick, he began doing research on the electrolyte used in calcium-air batteries.

Lu found when a single electrode is repeatedly charged and discharged, initially no reversibility can be observed, but after a few dozen cycles it gradually displays some reversibility. Surprisingly, the result seemed completely different from those in literature. The research team conducted a series of experiments aimed at uncovering the mechanism behind this phenomenon. On the electrode surface, the discharge products form a calcium oxide (CaxOy) interlayer, where the discharge product of oxygen, known as superoxide, is confined, allowing the superoxide to be then readily oxidized. This suggests the oxygen could probably be repeatedly oxidized/reduced, so that the cell can be continuously discharged/recharged.

Dr. Alex Neale, a Liverpool postdoctoral researcher, who is also part of the research team, said that through systematic electrochemical and spectroscopy investigations, the team began to understand the origins of this charge storage mechanism that facilitates a previously unseen degree of reversibility for systems based on the calcium-air battery.

Prof. Hardwick said the team will focus on designing new battery systems that use this newly discovered charge storage mechanism. He added that it was the cooperative research that made their discovery possible, and there are plans for even closer cooperation between NTHU and UoL in the future.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye